MedTrace Logo

GA-68 DOTA-TOC of Somatostatin Positive Malignancies

NCT02177773 · Status: TERMINATED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 300

Last updated 2019-11-12

Study results available
· View outcomes & findings →

Summary

This phase I/II trial studies how well gallium Ga 68-DOTA-TOC positron emission tomography (PET)/computed tomography (CT) or PET/magnetic resonance imaging (MRI) works in imaging patients with somatostatin receptor positive tumors. Gallium Ga 68-DOTA-TOC binds to somatostatin receptor positive tumors and can be seen using a PET scan. A PET scan uses a special camera to detect energy given off from gallium Ga 68-DOTA-TOC, to make detailed pictures of areas where material accumulates in the body. Diagnostic procedures, such as gallium Ga 68-DOTA-TOC PET/CT or PET/MRI, may help find and diagnose somatostatin receptor positive tumors and help plan the best treatment.

Conditions

  • Neuroendocrine Tumor
  • Paraganglioma
  • Carcinoid Tumors
  • Neuroblastoma

Interventions

PROCEDURE

Computed Tomography (CT)

Undergo Gallium Ga 68-DOTA-TOC PET/CT

DRUG

Gallium Ga 68-Edotreotide

Given Intravenously (IV) before imaging

PROCEDURE

Magnetic Resonance Imaging (MRI)

Undergo gallium Ga 68-DOTA-TOC PET/MRI

PROCEDURE

Positron Emission Tomography (PET)

Undergo gallium Ga 68-DOTA-TOC PET in combination with CT or MRI

Sponsors & Collaborators

Principal Investigators

  • Thomas A Hope, MD · University of California, San Francisco

Study Design

Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
2 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-06-23
Primary Completion
2017-08-07
Completion
2017-08-07
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02177773 on ClinicalTrials.gov